Tilray Inc (NASDAQ:TLRY – Get Free Report) shares fell 2.5% on Friday . The company traded as low as $1.73 and last traded at $1.74. 4,581,489 shares traded hands during trading, a decline of 82% from the average session volume of 24,963,607 shares. The stock had previously closed at $1.78.
Tilray Price Performance
The company has a current ratio of 2.27, a quick ratio of 1.42 and a debt-to-equity ratio of 0.10. The company’s 50 day moving average is $1.82 and its 200-day moving average is $1.87. The stock has a market cap of $1.45 billion, a PE ratio of -3.94 and a beta of 2.13.
Tilray (NASDAQ:TLRY – Get Free Report) last released its quarterly earnings results on Monday, July 29th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. The business had revenue of $229.90 million during the quarter, compared to analyst estimates of $226.20 million. During the same quarter last year, the firm posted ($0.15) EPS. The company’s revenue was up 24.8% compared to the same quarter last year. As a group, sell-side analysts predict that Tilray Inc will post -0.16 earnings per share for the current year.
Institutional Investors Weigh In On Tilray
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Read More
- Five stocks we like better than Tilray
- Where Do I Find 52-Week Highs and Lows?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Investing In Automotive Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What Are Dividend Champions? How to Invest in the Champions
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.